Abstract
AL-1 is a novel andrographolide derivative synthesized by conjugating andrographolide and alpha lipoic acid. AL-1 has been found to increase insulin secretion, decrease blood glucose level and protect β-cell mass and function in alloxan-induced diabetic mouse model. However, the protective mechanism of AL-1 on high glucose-induced pancreatic β-cell injury is still not clear. In the present study, we found that AL-1 reduced reactive oxygen species (ROS) and nitric oxide (NO) generation induced by high glucose in RIN-m cells, and which elevated the activities of superoxide dismutase (SOD) and catalase (CAT). In addition, AL-1 increased the expression of NF-E2-related factor 2 (Nrf2), thioredoxin-1 (Trx-1) and heme oxygenase-1 (HO- 1) proteins in RIN-m cells. These results suggest that AL-1 prevented RIN-m cells from high glucose-induced oxidative damage via upregulation of Nrf2 signaling pathway.
Keywords: Andrographolide, α-Lipoic acid, Nrf2, ROS.
Current Pharmaceutical Design
Title:Protective effects of andrographolide derivative AL-1 on high glucose-induced oxidative stress in RIN-m cells
Volume: 22 Issue: 4
Author(s): Hui Yan, Yongmei Li, Yali Yang, Zaijun Zhang, Gaoxiao Zhang, Yewei Sun, Pei Yu, Yuqiang Wang and Lipeng Xu
Affiliation:
Keywords: Andrographolide, α-Lipoic acid, Nrf2, ROS.
Abstract: AL-1 is a novel andrographolide derivative synthesized by conjugating andrographolide and alpha lipoic acid. AL-1 has been found to increase insulin secretion, decrease blood glucose level and protect β-cell mass and function in alloxan-induced diabetic mouse model. However, the protective mechanism of AL-1 on high glucose-induced pancreatic β-cell injury is still not clear. In the present study, we found that AL-1 reduced reactive oxygen species (ROS) and nitric oxide (NO) generation induced by high glucose in RIN-m cells, and which elevated the activities of superoxide dismutase (SOD) and catalase (CAT). In addition, AL-1 increased the expression of NF-E2-related factor 2 (Nrf2), thioredoxin-1 (Trx-1) and heme oxygenase-1 (HO- 1) proteins in RIN-m cells. These results suggest that AL-1 prevented RIN-m cells from high glucose-induced oxidative damage via upregulation of Nrf2 signaling pathway.
Export Options
About this article
Cite this article as:
Yan Hui, Li Yongmei, Yang Yali, Zhang Zaijun, Zhang Gaoxiao, Sun Yewei, Yu Pei, Wang Yuqiang and Xu Lipeng, Protective effects of andrographolide derivative AL-1 on high glucose-induced oxidative stress in RIN-m cells, Current Pharmaceutical Design 2016; 22 (4) . https://dx.doi.org/10.2174/1381612821666150921110716
DOI https://dx.doi.org/10.2174/1381612821666150921110716 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Emerging Therapeutic Targets in Regenerative Medicine for the Treatment of Diabetes Mellitus: A Patent Literature Review
Recent Patents on Regenerative Medicine Recent Pharmacoproteomics Studies of Warfarin in the Asia-Pacific: A New Strategy for Personalized Medicine?
Current Pharmacogenomics and Personalized Medicine Dietary Compounds, Epigenetic Modifications and Metabolic Diseases
Current Chemical Biology Biocompatibility and Biotolerability Assessment of Microspheres Using a Whole Blood Model
Micro and Nanosystems Non-Alcoholic Fatty Pancreas Disease (NAFPD): A Silent Spectator or the Fifth Component of Metabolic Syndrome? A Literature Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Osteogenic Differentiation Factors of Multipotent Mesenchymal Stromal Cells in the Current Understanding
Current Pharmaceutical Design Do Not Say Ever Never More: The Ins and Outs of Antiangiogenic Therapies
Current Pharmaceutical Design Role of the Akt Pathway in Prostate Cancer
Current Cancer Drug Targets The IGF-I Signaling Pathway
Current Pharmaceutical Design Recent Advances in Targeting Nuclear Molecular Imaging Driven by Tetrazine Bioorthogonal Chemistry
Current Medicinal Chemistry Editorial (Thematic Issue: Immunophilins, Protein Chemistry and Cell Biology of a Promising New Class of Drug Targets – Part II)
Current Molecular Pharmacology Cell Penetrating Peptides for In Vivo Molecular Imaging Applications
Current Pharmaceutical Design SAGE Application in the Study of Diabetes
Current Pharmaceutical Biotechnology Practical Application of Antidiabetic Efficacy of <i>Lycium barbarum</i> Polysaccharide in Patients with Type 2 Diabetes
Medicinal Chemistry The Biology of TRAIL and the Role of TRAIL-Based Therapeutics in Infectious Diseases
Anti-Infective Agents in Medicinal Chemistry Clinical Pharmacology of Cyclophosphamide and Ifosfamide
Current Drug Therapy Disruption of Metabolic Pathways - Perspectives for the Treatment of Cancer
Current Cancer Drug Targets Regulatory T-Cells: Immunomodulators in Health and Disease
Current Topics in Medicinal Chemistry Sigma-1 Receptor Chaperones and Diseases
Central Nervous System Agents in Medicinal Chemistry Angiotensin Converting Enzyme-2: A Doorway for SARS-CoV-2
Coronaviruses